Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | AGPAT2 | O15120 | 9/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29609567 | 0.80 | POLA1 (0.67) | POLA1MAPTSMN1; SMN2GAAPOLB | |
| SCHEMBL28229117 | 0.80 | POLA1 (0.67) | POLA1MAPTSMN1; SMN2GAAPOLB | |
| SCHEMBL3233125 | 0.80 | MAPT (0.70) | POLA1MAPTSMN1; SMN2GAAPOLB | |
| SCHEMBL1320467 | 0.79 | KMT2A (0.66) | POLA1MAPTSMN1; SMN2GAAPOLB | |
| SCHEMBL4281760 | 0.79 | AGPAT2 (0.79) | AGPAT2 | |
| SCHEMBL4286763 | 0.78 | AGPAT2 (0.79) | AGPAT2CYP2C19NPC1RAB9ACYP1A2 | |
| SCHEMBL17815607 | 0.78 | ROCK1 (0.61) | POLA1MAPTSMN1; SMN2GAAPOLB | |
| SCHEMBL14450270 | 0.76 | MAPT (0.65) | POLA1MAPTSMN1; SMN2GAAPOLB | |
| SCHEMBL2879724 | 0.76 | POLA1 (0.61) | POLA1MAPTSMN1; SMN2GAAPOLB | |
| SCHEMBL13288391 | 0.76 | MAPT (1.00) | POLA1MAPTSMN1; SMN2GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | POLA1 507/4885MAPT 3800/4885SMN1; SMN2 4131/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | POLA1 420/4885MAPT 3707/4885SMN1; SMN2 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.